diff --git a/cntr-monitor/content/en/issues/2024/posts/8_oncolytic.mdx b/cntr-monitor/content/en/issues/2024/posts/8_oncolytic.mdx
index 4426f2e4..ac6f0b24 100644
--- a/cntr-monitor/content/en/issues/2024/posts/8_oncolytic.mdx
+++ b/cntr-monitor/content/en/issues/2024/posts/8_oncolytic.mdx
@@ -39,7 +39,7 @@ While viral engineering may be crucial for developing effective therapeutics, th
 
 ## Choice of Virus for Oncolytic Virotherapy
 
-The dual-use potential of oncolytic virus research depends on how directly viral engineering insights may be applied to pathogens. Thus, the choice of viral vectors significantly influences dual-use risk. In contrast to other therapeutic applications of viruses, for instance for gene therapy, there is a particularly high chance of oncolytic virus research involving viruses related to human pathogens. An effective oncolytic virus can replicate in humans, have cancer-killing activity, and induce immune responses that can kill bystander tumor cells. Thus, among the ten virus families explored in clinical trials of oncolytic virotherapy are high-risk viruses such as the influenza, measles, and variola viruses (see Table 1). Influenza and measles viruses are both human pathogens against which a significant share of the population is immunized. Insights into the enhancement of these viruses, especially relating to the property of evading vital immune responses, could pose significant public health risks.
+The dual-use potential of oncolytic virus research depends on how directly viral engineering insights may be applied to pathogens. Thus, the choice of <Term t="viraler-vektor">viral vectors</Term> significantly influences dual-use risk. In contrast to other therapeutic applications of viruses, for instance for gene therapy, there is a particularly high chance of oncolytic virus research involving viruses related to human pathogens. An effective oncolytic virus can replicate in humans, have cancer-killing activity, and induce immune responses that can kill bystander tumor cells. Thus, among the ten virus families explored in clinical trials of oncolytic virotherapy are high-risk viruses such as the influenza, measles, and variola viruses (see Table 1). Influenza and measles viruses are both human pathogens against which a significant share of the population is immunized. Insights into the enhancement of these viruses, especially relating to the property of evading vital immune responses, could pose significant public health risks.
 
 <Figure src="assets/iStock-1383260152_web.jpg" caption="Oncolytic viruses are a group of replicating viruses that preferentially infect and kill cancer cells. Picture: iStock, luismmolina." alt="Illustration of a tumor cell from which further branches extend; four viruses are docked to the node in the middle." />